Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/08/26	US$14.11	-1.74%	35,062
07/08/26	US$14.36	+0.70%	43,809
06/08/26	US$14.26	-1.04%	23,754
05/08/26	US$14.41	+0.07%	29,947
04/08/26	US$14.40	+1.84%	76,833

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

14.11USD

Average target price

12.00USD

Spread / Average Target

-14.95%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 11/08/2026 HKT			5-day change	1st Jan Change
14.11 ^USD	-1.74%		-0.21%	+1.11%

07-30	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-30	Tranche Update on Amarin Corporation plc's Equity Buyback Plan announced on May 1, 2024.	CI

Market Cap	298M 258M 241M 220M 415M 28.43B 422M 2.83B 1.11B 14.22B 1.12B 1.09B 47.36B	P/E 2026 *	-202x	P/E 2027 *	-235x
Enterprise Value	142M 123M 115M 105M 198M 13.54B 201M 1.35B 529M 6.77B 533M 521M 22.56B	EV / Sales 2026 *	0.83x	EV / Sales 2027 *	0.86x
Free-Float	86.93%	Yield 2026 *	-	Yield 2027 *	-

07-30	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-30	Tranche Update on Amarin Corporation plc's Equity Buyback Plan announced on May 1, 2024.	CI
07-30	European Equities Traded in US as ADRs Ease in Wednesday Trading	MT
07-29	Amarin Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-02	European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	MT
07-01	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI
06-29	European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading	MT
06-24	Top cases on the US Supreme Court's docket	RE
06-22	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
06-18	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
06-09	European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading	MT
06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
06-05	The Jobs Report Just Made the Fed's Life Harder

27/10/25	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/06/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/10/23	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/07/23	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/01/23	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT

Amarin Corporation plc Stock

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Valuation: Amarin Corporation plc

Chart: Amarin Corporation plc

Latest news : Amarin Corporation plc

Last Transcript: Amarin Corporation plc

Analysts' recommendations: Amarin Corporation plc

Press Releases: Amarin Corporation plc

News in other languages: Amarin Corporation plc

Quotes and Performance

Course Extremes

Managers and Directors: Amarin Corporation plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-29	Amarin: Q2 Earnings Snapshot	AQ
07-29	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence	AQ
07-15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026	AQ
07-01	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	AQ
05-27	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ

06-05	Afternoon Meeting: Los datos de empleo complican la labor de la Fed
06-05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE
30/07/25	Recordati : firmato contratto di licenza e fornitura con Amarin per 25mln $ (RCO)
24/06/25	Recordati e Amarin commercializzano il farmaco cardiovascolare Vazkepa
30/03/22	Amarin reçoit un remboursement pour VAZKEPA® en Suède

1 day	-1.74%
1 week	-0.21%
Current month	-1.05%
1 month	-5.17%
3 months	-6.25%
6 months	-6.06%
Current year	+1.11%

1 week	13.96	14.6
1 month	13.47	14.97
Current year	12.96	17.31
1 year	12.96	20.9
3 years	7.08	27.4
5 years	7.08	119.4
10 years	7.08	522.4

Manager	Title	Age	Since
Aaron Berg CEO	Chief Executive Officer	63	04/06/2024
Peter Fishman DFI	Director of Finance/CFO	42	23/10/2024
Jonathan Provoost CMP	Compliance Officer	56	15/11/2023

Director	Title	Age	Since
Aaron Berg BRD	Director/Board Member	63	04/06/2024
Patrice Bonfiglio BRD	Director/Board Member	43	28/02/2023
Keith Horn BRD	Director/Board Member	67	28/02/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/8/26	Peter Fishman	Fiscal year	Chief Financial Officer	781	0.0002%
1/7/26	David Keenan	Fiscal year	Chief Operating Officer	9,302	0.0022%
1/7/26	Steven Ketchum	Fiscal year	Chief Technology Officer	9,263	0.0022%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMARIN CORPORATION PLC	-1.74%	-0.21%	-5.87%	-36.44%	303M
WUXI APPTEC CO., LTD.	+4.21%	+25.56%	+77.96%	+104.49%	68.12B
ARGENX SE	+0.50%	+6.20%	+34.94%	+67.83%	55.18B
INSMED INCORPORATED	+2.78%	+36.87%	+23.00%	+493.09%	28.63B
WUXI BIOLOGICS (CAYMAN) INC.	+2.91%	+18.87%	+57.08%	+5.18%	23.99B
BIONTECH SE	-0.93%	+0.60%	-16.89%	-12.00%	23.53B
GENMAB A/S	-0.35%	+7.91%	+44.14%	-22.61%	18.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.28%	+10.84%	+31.14%	+628.97%	16.44B
PHARMAESSENTIA CORPORATION	+7.26%	+14.16%	+221.03%	+393.89%	15.83B
EXELIXIS, INC.	-2.05%	-3.81%	+40.40%	+150.40%	13.4B
Average	+0.82%	+8.93%	+50.69%	+177.28%	26.39B
Weighted average by Cap.	+1.64%	+11.46%	+53.94%	+162.88%

	2026 *	2027 *
Net sales	172M 149M 139M 127M 239M 16.36B 243M 1.63B 639M 8.18B 644M 630M 27.26B	165M 143M 133M 122M 229M 15.7B 233M 1.56B 613M 7.85B 618M 605M 26.16B
Net income	-29.68M -25.69M -24.02M -21.95M -41.36M -2.83B -42.01M -282M -111M -1.42B -111M -109M -4.72B	-23.48M -20.33M -19M -17.36M -32.72M -2.24B -33.23M -223M -87.42M -1.12B -88.17M -86.24M -3.73B
Net Debt	-156M -135M -126M -115M -218M -14.89B -221M -1.48B -581M -7.45B -586M -573M -24.8B	-156M -135M -126M -115M -217M -14.86B -220M -1.48B -580M -7.43B -585M -572M -24.75B